Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer

This publication has 19 references indexed in Scilit:

• The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes
  Gynecologic Oncology, 2022
• Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
  The Lancet, 2022
• Integrated mutational landscape analysis of uterine leiomyosarcomas
  Proceedings of the National Academy of Sciences, 2021
• Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study
  The Lancet Oncology, 2020
• β2-AR blockade potentiates MEK1/2 inhibitor effect on HNSCC by regulating the Nrf2-mediated defense mechanism
  Cell Death & Disease, 2020
• Low-grade serous ovarian cancer: State of the science
  Gynecologic Oncology, 2020
• Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase
  Gynecologic Oncology, 2016
• The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer
  Gynecologic Oncology, 2015
• Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors
  Cancer Cell, 2014
• Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant
  Gynecologic Oncology, 2009